Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV
Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today announced positive results from the multicenter, single-arm Phase 2b SPOTLIGHT‑204 clinical trial evaluating BO‑112, a novel dsRNA-based intralesional treatment for patients with resectable primary low‑ and high‑risk basal cell carcinoma (BCC).
Read original article on The Medical News →Related news
-
Metabolite-inspired compounds show promise for ulcerative colitis drug discovery
United Kingdom
-
Adolescents often choose to eat outside school, Swedish study finds
United Kingdom
-
For older adults, disaster risk starts long before disaster strikes
United Kingdom
-
Same-day chemotherapy boosts cancer vaccine responses in preclinical models
United Kingdom
-
Seaweed strandings cause a stink—here's why they harm your health
United Kingdom
-
The risk of looking back at former versions of ourselves
United Kingdom
-
What your eyes could reveal about your heart health
United Kingdom
-
Hidden lymphatic signal amplifier could inform treatments for lymphedema and cancer metastasis
United Kingdom